Kewaunee Scientific Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4928541048
USD
39.27
1.16 (3.04%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Kewaunee Scientific Corp. stock-summary
stock-summary
Kewaunee Scientific Corp.
Pharmaceuticals & Biotechnology
Kewaunee Scientific Corporation is engaged in the design, manufacture and installation of laboratory, healthcare and technical furniture products. The Company's products include steel, wood and laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. It operates through two segments: Domestic and International. The Domestic business segment designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, worksurfaces, workstations, workbenches, and computer enclosures. The International business segment provides facility design, engineering, construction and project management from the planning stage through testing and commissioning of laboratories.
Company Coordinates stock-summary
Company Details
2700 W Front St , STATESVILLE NC : 28677
stock-summary
Tel: 1 704 8737202
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 10 Schemes (15.6%)

Foreign Institutions

Held by 14 Foreign Institutions (2.81%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. David Rhind
Independent Chairman of the Board
Mr. Thomas Hull
President, Chief Executive Officer, Director
Mr. Keith Gehl
Independent Director
Ms. Margaret Pyle
Independent Director
Mr. John Russell
Independent Director
Mr. Donald Shaw
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
77 Million
(Quarterly Results - Apr 2025)
Net Profit:
5 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 162 Million (Micro Cap)

stock-summary
P/E

6.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.39

stock-summary
Return on Equity

17.97%

stock-summary
Price to Book

2.51